Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Beijing Sun-Novo Pharmaceutical Research Co Ltd
SSE:688621
Price:
58.78
CNY
0.36%
Market Cap:
¥6.6B
Balance Sheet
Balance Sheet Decomposition
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Balance Sheet Decomposition is not available for
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Balance Sheet
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Beijing Sun-Novo Pharmaceutical Research Co Ltd
Currency: CNY
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
32
|
77
|
109
|
490
|
609
|
691
|
566
|
|
| Cash |
32
|
77
|
109
|
490
|
609
|
691
|
566
|
|
| Short-Term Investments |
0
|
0
|
5
|
158
|
13
|
30
|
50
|
|
| Total Receivables |
71
|
84
|
120
|
258
|
379
|
574
|
793
|
|
| Accounts Receivables |
56
|
75
|
111
|
230
|
358
|
545
|
754
|
|
| Other Receivables |
15
|
8
|
9
|
28
|
21
|
29
|
39
|
|
| Inventory |
4
|
4
|
6
|
8
|
13
|
14
|
15
|
|
| Other Current Assets |
12
|
18
|
22
|
28
|
27
|
48
|
90
|
|
| Total Current Assets |
119
|
182
|
263
|
942
|
1 040
|
1 357
|
1 514
|
|
| PP&E Net |
54
|
65
|
76
|
193
|
206
|
246
|
213
|
|
| PP&E Gross |
54
|
65
|
76
|
193
|
206
|
246
|
213
|
|
| Accumulated Depreciation |
11
|
16
|
27
|
53
|
87
|
129
|
140
|
|
| Intangible Assets |
2
|
4
|
4
|
3
|
4
|
5
|
5
|
|
| Goodwill |
21
|
21
|
26
|
26
|
26
|
26
|
26
|
|
| Long-Term Investments |
0
|
0
|
0
|
40
|
95
|
101
|
116
|
|
| Other Long-Term Assets |
6
|
15
|
16
|
38
|
92
|
127
|
112
|
|
| Other Assets |
21
|
21
|
26
|
26
|
26
|
26
|
26
|
|
| Total Assets |
202
N/A
|
286
+42%
|
385
+35%
|
1 243
+223%
|
1 463
+18%
|
1 863
+27%
|
1 987
+7%
|
|
| Liabilities | ||||||||
| Accounts Payable |
9
|
16
|
14
|
18
|
33
|
57
|
38
|
|
| Accrued Liabilities |
8
|
15
|
22
|
26
|
35
|
50
|
56
|
|
| Short-Term Debt |
2
|
12
|
24
|
139
|
202
|
385
|
310
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
19
|
23
|
22
|
44
|
|
| Other Current Liabilities |
105
|
124
|
132
|
216
|
225
|
248
|
331
|
|
| Total Current Liabilities |
124
|
167
|
192
|
418
|
518
|
761
|
779
|
|
| Long-Term Debt |
0
|
0
|
0
|
50
|
34
|
41
|
102
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Minority Interest |
1
|
2
|
4
|
8
|
12
|
17
|
2
|
|
| Other Liabilities |
4
|
0
|
0
|
6
|
3
|
4
|
3
|
|
| Total Liabilities |
126
N/A
|
169
+34%
|
196
+16%
|
481
+146%
|
566
+18%
|
823
+45%
|
887
+8%
|
|
| Equity | ||||||||
| Common Stock |
16
|
16
|
60
|
80
|
80
|
112
|
112
|
|
| Retained Earnings |
31
|
78
|
76
|
182
|
317
|
454
|
613
|
|
| Additional Paid In Capital |
28
|
22
|
53
|
500
|
500
|
474
|
376
|
|
| Total Equity |
75
N/A
|
117
+55%
|
189
+62%
|
762
+303%
|
897
+18%
|
1 040
+16%
|
1 101
+6%
|
|
| Total Liabilities & Equity |
202
N/A
|
286
+42%
|
385
+35%
|
1 243
+223%
|
1 463
+18%
|
1 863
+27%
|
1 987
+7%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
112
|
112
|
112
|
112
|
112
|
112
|
112
|
|
Switch to:
Switch to:
See Also
Discover More
